Muthu Veeraputhiran

Associate Professor

UAMS
Last publication 2024 Last refreshed 2026-05-16

faculty

Internal Med, College of Medicine

10 h-index 57 pubs 375 cited

Research Areas

Links

Research Group UAMS TRI Profile

OverviewAI-generated summary

Dr. Muthu Veeraputhiran's research focuses on hematologic malignancies and stem cell transplantation, particularly investigating outcomes and treatment strategies for relapsed/refractory B-cell acute lymphoblastic leukemia (ALL).

His work includes analyzing the efficacy of CAR T-cell therapies, such as brexucabtagene autoleucel, in adult patients with B-cell ALL, examining real-world outcomes and the impact of prior treatments. Dr. Veeraputhiran also studies combination therapies for graft-versus-host disease, including the use of belumosudil and ruxolitinib, and explores treatment approaches for diffuse large B-cell lymphoma prior to CAR-T therapy.

He has published on immune effector cell-associated HLH-like syndrome and the diagnostic challenges of intravascular large B-cell lymphoma. Dr. Veeraputhiran holds an h-index of 10 with 56 publications and 360 citations. He collaborates with researchers at the University of Arkansas for Medical Sciences, including Akash Mukherjee, with whom he has 15 shared publications.

Research Overview

Dr. Muthu Veeraputhiran is a physician in the University of Arkansas for Medical Sciences (UAMS) Department of Internal Medicine. Dr. Veeraputhiran received his medical degree from the Stanley Medical College in his native India. He went on to receive a Masters of Public health from the University of Oklahoma. He then completed residency training in Internal Medicine at Abington Memorial Hospital in Pennsylvania. He has also completed fellowships in Transfusion Medicine at UAMS, Hematology, Oncology, and Bone Marrow Transplantation at Wayne State University, and Bone Marrow Transplantation at Stanford University. Dr. Veeraputhiran is board certified in Clinical Cardiac Electrophysiology from the American Board of Internal Medicine. He is a member of several professional organizations, including the American Society for Blood and Marrow Transplantation, the American Association for Blood Banks, the American Board of Internal Medicine, the American Society of Hematology, and the American Society of Oncology.

Metrics

  • h-index: 10
  • Publications: 57
  • Citations: 375

Selected Publications

  • Real-World Experience with Narsoplimab (OMS721) for the Treatment of Transplant-Associated Thrombotic Microangiopathy (2024)
    1 citation DOI OpenAlex
  • Assessment of Central Nervous System Responses in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Brexucabtagene Autoleucel As an FDA-Approved Standard of Care (2024)
    5 citations DOI OpenAlex
  • Belumosudil and ruxolitinib combination for treatment of refractory chronic graft-versus-host disease (2023)
    18 citations DOI OpenAlex
  • Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA) (2023)
    4 citations DOI OpenAlex
  • Brexucabtagene Autoleucel in Adults with Relapsed/Refractory B-Cell ALL: Outcomes and Novel Insights from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA) (2023)
    14 citations DOI OpenAlex
  • The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (2023)
    1 citation DOI OpenAlex
  • Toxicity Profile of Brexucabtagene Autoleucel (brexu-cel; CD19-directed CAR T-cell therapy) in Adult Patients (pts) with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from a Multicenter Real-World Outcomes Study (2023)
    1 citation DOI OpenAlex
  • Impact of Prior Response to Blinatumomab on Outcomes of Brexucabtagene Autoleucel (Brexu-cel) in Adult Patients with Relapsed or Refractory (r/r) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA) (2023)
    4 citations DOI OpenAlex
  • The Impact of Inotuzumab Ozogamicin (InO) Treatment on Brexucabtagene Autoleucel (Brexu-cel) Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL) (2023)
    4 citations DOI OpenAlex
  • Interdigitating Dendritic Cell Sarcoma and Indeterminate Dendritic Cell Tumor: Patient Characteristics, Prognostic Factors, and Survival Outcomes for Rare Dendritic Cell Neoplasms (2023)
    DOI OpenAlex
  • Immune Effector Cell-Associated HLH-like Syndrome: A Review of the Literature of an Increasingly Recognized Entity (2023)
    25 citations DOI OpenAlex
  • Sleep-wake Disturbance following Allogeneic Hematopoietic Stem Cell Transplantation: Trajectory and Correlates (2023)
    1 citation DOI OpenAlex
  • Tafasitamab (TAFA) Plus Lenalidomide (LEN) Prior to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Case Series of 8 Patients (2022)
    5 citations DOI OpenAlex
  • Is heart rate in post-hematopoietic stem cell transplant patients clinically relevant? (2021)
    1 citation DOI OpenAlex
  • Intravascular Large B-Cell Lymphoma: A Diagnostic Dilemma (2021)
    10 citations DOI OpenAlex

View all publications on OpenAlex →

Grants & Funding

  • Benton County REACH Covid Health Literacy DHHS - Office of Minority Health - Pass Through: Benton County Government Principal Investigator
  • No FP attached Kadmon Corporation, LLC Principal Investigator
  • No FP attached NIH/Nat. Cancer Institute - Pass Through: Alliance for Clinical Trials in Oncology Principal Investigator
  • A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (VIALE-T) AbbVie Inc Principal Investigator
  • A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of CYP-001 in Combination with Corticosteroids vs Corticosteroids Alone for the Treatment of High-Risk Acute Graft Versus Host Disease Cynata Therapeutics Principal Investigator
  • No FP attached Agios Pharmaceuticals, Inc. Principal Investigator
  • A Randomized, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Belumosudil Plus Corticosteroids vs Placebo Plus Corticosteroids in Participants =12 Years With Newly Diagnosed Chronic Graft-Versus-Host Disease (cGVHD) Sanofi US Services Principal Investigator
  • GRAVITAS-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (239545) Incyte Corporation Principal Investigator

Collaboration Network

109 Collaborators 51 Institutions 1 Country

Top Collaborators

View profile →

Similar Researchers

Based on overlapping research topics

Akash Mukherjee University of Arkansas for Medical Sciences
Hematopoietic Stem Cell Transplantation Acute Lymphoblastic Leukemia research CAR-T cell therapy research
Good match 5 shared topics
Mamatha Gaddam University of Arkansas for Medical Sciences
Hematopoietic Stem Cell Transplantation CAR-T cell therapy research Cancer Treatment and Pharmacology
Good match 5 shared topics
Michael R. Bishop University of Arkansas for Medical Sciences
Hematopoietic Stem Cell Transplantation Acute Lymphoblastic Leukemia research CAR-T cell therapy research
Good match 5 shared topics
Jaskirat Sethi University of Arkansas for Medical Sciences
Hematopoietic Stem Cell Transplantation CAR-T cell therapy research Cancer Treatment and Pharmacology
Good match 4 shared topics
Lauren Appell University of Arkansas for Medical Sciences
Hematopoietic Stem Cell Transplantation CAR-T cell therapy research Cancer Treatment and Pharmacology
Good match 4 shared topics
Appalanaidu Sasapu University of Arkansas for Medical Sciences
Hematopoietic Stem Cell Transplantation CAR-T cell therapy research Cancer Treatment and Pharmacology
Good match 4 shared topics